Join
Live feed
·
PRReleasevia Quantisnow
Candel Therapeutics Inc. logo

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CADL· Candel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CADL (Candel Therapeutics Inc.) and more on Quantisnow.